Showing results (1-10 of 80) with videos related to
Sort By:
Pageof 8
BMJ Case Reports|November 4, 2018
Multifocal avascular osteonecrosis despite appropriate anticoagulation therapy in a patient with systemic lupus erythematosus and antiphospholipid syndromeIrene Cecchi, Laura Pérez Sánchez, Savino Sciascia, et al.Lupus|May 20, 2025
JAK inhibitors for the management of rheumatic diseases when antiphospholipid syndrome co-exists: case-based safety considerationsSantiago Dans-Caballero, Irene Cecchi, Massimo Radin, et al.Seminars in Thrombosis and Hemostasis|August 5, 2017
Prevalence and Thrombotic Risk Assessment of Anti-β2 Glycoprotein I Domain I Antibodies: A Systematic ReviewMassimo Radin, Irene Cecchi, Dario Roccatello, et al.Lupus|May 27, 2021
16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndromeSavino Sciascia, Massimo Radin, Irene Cecchi, et al.Seminars in Arthritis and Rheumatism|May 12, 2018
Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndromeSavino Sciascia, Massimo Radin, Irene Cecchi, et al.Clinical and Experimental Rheumatology|February 26, 2021
An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritisDaniela Rossi, Irene Cecchi, Savino Sciascia, et al.Rheumatology (Oxford, England)|January 18, 2018
Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysisSavino Sciascia, Massimo Radin, Giovanni Sanna, et al.Rheumatology International|March 5, 2017
Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidenceSavino Sciascia, Massimo Radin, Jinoos Yazdany, et al.EULAR Rheumatology Open|August 1, 2026
Risk-benefit considerations for antirheumatic drug use in pregnancy, breastfeeding, and male preconception: expert perspectivesAndrea Pluma, Linda Rüegg, Sabrina Hamroun, et al.Rheumatology (Oxford, England)|February 5, 2016
Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndromeSavino Sciascia, Chary Lopez-Pedrera, Irene Cecchi, et al.Pageof 8